Experimental Design and Consultation
Collaborate closely with clients to define target genes, mutation sites, cell types, and editing strategies.
Precise point mutation introduction is a key technical approach for studying gene function, dissecting disease mechanisms, and validating therapeutic targets. Alfa Cytology offers point mutation services based on CRISPR-mediated editing and Prime Editing technologies to enable precise single-nucleotide alterations in target genes. Leveraging our optimized editing strategies and rigorous clonal selection workflows, we deliver high-quality point mutation models to support a broad range of applications—from functional genomics to disease research.
Point mutations, single-nucleotide substitutions, are central molecular events driving a wide spectrum of genetic disorders and cancers. The precise introduction of specific point mutations enables researchers to model disease-associated genetic variants and dissect their impact on protein function and cellular behavior. Conventional approaches, such as CRISPR/Cas9 combined with ssODN donor templates via the homology-directed repair (HDR) pathway, have been widely adopted for point mutation introduction. However, HDR-mediated editing is often constrained by low efficiency, dependence on the cell cycle, and the requirement for donor templates. To overcome these limitations, the next-generation Prime Editing technology has emerged as a transformative tool. Prime Editing enables all 12 types of base-to-base conversions as well as small insertions and deletions, without requiring DNA double-strand breaks or donor templates. This unique mechanism significantly reduces the risk of unintended editing outcomes and offers distinct advantages for modeling complex mutations that are challenging to generate using conventional methods. By providing greater precision and flexibility, Prime Editing is expanding the possibilities for disease modeling, functional genomics, and therapeutic development.
Fig. 1 Principles of CRISPR–Cas9, base editing, and prime editing as enabling technologies for point mutation introduction. (Yu J, et al.; 2026)
Leveraging our deep expertise in CRISPR gene editing and precision mutation introduction, Alfa Cytology provides end-to-end point mutation services tailored to meet your specific research needs. Our comprehensive service portfolio covers a wide range of options to accommodate diverse research scenarios and project requirements.
Our standard service utilizes CRISPR/Cas9 and ssODN donor-mediated HDR repair to achieve precise single-nucleotide alterations in target genes, applicable to conventional cell lines (HEK293, HCT116, A375, etc.) and a variety of research scenarios. Service include:
For applications where HDR efficiency is limiting or where greater editing precision is required, we offer point mutation services based on prime editing. Service include:
We offer comprehensive solutions ranging from HDR-mediated standard point mutation to prime editing point mutation and customized point mutation services, covering conventional cell lines as well as challenging cell types such as primary cells and stem cells.
| Service Type | Service Details | Applicable Cell Lines | Validation Methods |
| Standard Point Mutation (HDR-Mediated) | Precise single-nucleotide alterations based on CRISPR/Cas9 and ssODN donor | Wide range of common cancer cell lines (HEK293, HCT116, A375, etc.) |
|
| Prime Editing Point Mutation | All 12 types of base conversions and small insertions/deletions via prime editing | Multiple cell lines (including cell types with limited HDR efficiency) |
|
| Customized Point Mutation | Custom strategies for non-conventional cell lines or specific experimental requirements | Any cell line, including organoids | Custom validation protocols based on project requirements |
For challenging cell types with limited editing efficiency, such as primary cells and stem cells, we offer optimized delivery systems including RNP electroporation and lentiviral transduction to achieve efficient point mutation introduction while preserving cell viability.
Leveraging a dual-technology platform combining CRISPR/HDR and Prime Editing, we provide comprehensive mouse model generation services, from standard point mutation and prime editing point mutation to fully customized point mutation, supporting in vivo functional studies and disease model development.
| Service Type | Model Features | Validation Methods |
| Standard Point Mutation Mice (HDR-Mediated) | Introduction of specific point mutations via CRISPR/HDR; germline transmissible |
|
| Prime Editing Point Mutation Mice | Introduction of point mutations or small-fragment edits via Prime Editing platform; DSB-free; germline transmissible |
|
| Customized Point Mutation Mice | Custom mutation strategies tailored to specific experimental requirements | Custom validation protocols based on project requirements |
HDR-mediated point mutation is a reliable strategy for introducing standard point mutations and generating disease-related mouse models. Prime Editing is particularly suited for complex mutation scenarios where HDR efficiency is limited, especially for small-fragment insertions, deletions, and precise edits that are difficult to achieve through HDR.
Oncogenic Mutation Functional Studies
Introduce tumor-associated driver mutations (e.g., EGFR L858R, KRAS G12V/G12C, BRAF V600E, etc.) to investigate their effects on cell proliferation, migration, and drug response.
Patient-Specific Mutation Modeling
Introduce specific point mutations into cells or animal models based on patient genomic sequencing data to generate precise disease models that support the development of personalized therapeutic strategies.
Drug Target Validation
Introduce gain-of-function or loss-of-function point mutations in target genes to evaluate their impact on drug sensitivity, supporting the development and validation of targeted therapeutics.
Experimental Design and Consultation
Collaborate closely with clients to define target genes, mutation sites, cell types, and editing strategies.
Editing Strategy Design and Optimization
Design sgRNAs and donor templates (HDR) or pegRNAs. For Prime Editing, optimize pegRNA and nicking sgRNA designs to enhance editing efficiency.
Delivery and Editing
Deliver editing components into target cells using optimized transfection protocols. For prime editing, deliver the prime editing system components to achieve precise base conversion.
Preliminary Editing Efficiency Assessment
Harvest cells post-delivery, extract genomic DNA, and assess editing efficiency at the target site via T7EI assay or Sanger sequencing. Proceed to monoclonal selection only after confirming successful editing.
Monoclonal Selection and Validation
Isolate single-cell clones by limiting dilution and expand them for Sanger sequencing to verify precise point mutation introduction. Confirm homozygous mutant clones and exclude any unintended edits.
Dual-Platform Flexibility
HDR and Prime Editing technologies to match your specific editing needs.
DSB-Free Capability
Prime editing offers precise editing without double-strand breaks, minimizing off-target risks.
Exceptional Precision
Rigorous validation ensures accurate mutation introduction without unintended edits.
In Vitro to In Vivo Continuity
Seamless support for both cell lines and mouse models.
Precise point mutation models are essential tools for gene functional studies and the mechanistic dissection of disease pathogenesis. Alfa Cytology's point mutation services, powered by a dual-technology platform combining HDR-mediated and prime editing approaches, deliver high-quality, precisely engineered mutation models to support your entire research journey, from basic discovery to translational applications. Contact us today to learn how our point mutation services can meet your specific research needs.
Reference
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.